| Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. | |
| | |
MedLine Citation:
|
PMID: 16621151 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have previously shown that self-association of human vasoactive intestinal peptide with sterically stabilized liposomes (VIP-alpha) alters peptide conformation from random coil in aqueous solution to alpha-helix. This, in turn, protects the peptide from hydrolysis and amplifies and prolongs its bioactivity. The purpose of this study was to determine whether a single, intravenous injection of low-dose human VIP-alpha normalizes systemic arterial pressure in anesthetized spontaneously hypertensive hamsters for a prolonged period of time in a selective fashion. We found that intravenous injection of human VIP-alpha, VIP alone (each, 1.0 nmol) and empty liposomes had no significant effects on mean arterial pressure (MAP) in normotensive hamsters. By contrast, human VIP-alpha (0.01-1.0 nmol) evoked a significant concentration-dependent decrease in MAP to the normative range in spontaneously hypertensive hamsters that lasted throughout the observation period (6 h; p<0.05). VIP alone and empty liposomes had no significant effects on MAP in these animals. We conclude that a single, low-dose intravenous injection of human VIP-alpha normalizes systemic arterial pressure in spontaneously hypertensive hamsters for a prolonged period of time in a selective fashion. We suggest that human VIP-alpha should be further developed as a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. |
| | |
Authors:
|
Hayat Onyüksel; Florence Séjourné; Hideyuki Suzuki; Israel Rubinstein |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. Date: 2006-04-18 |
Journal Detail:
|
Title: Peptides Volume: 27 ISSN: 0196-9781 ISO Abbreviation: Peptides Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-08-15 Completed Date: 2006-11-07 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 8008690 Medline TA: Peptides Country: United States |
Other Details:
|
Languages: eng Pagination: 2271-5 Citation Subset: IM |
Affiliation:
|
Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, IL 60612, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / administration & dosage*, pharmacokinetics, therapeutic use Biocompatible Materials / chemistry Biodegradation, Environmental Cricetinae Humans Hypertension / drug therapy* Injections, Intravenous Male Nanostructures / chemistry Vasoactive Intestinal Peptide / administration & dosage*, pharmacokinetics, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
R01 AG024026/AG/NIA NIH HHS; R01 HL72343/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Biocompatible Materials; 37221-79-7/Vasoactive Intestinal Peptide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A hemoglobin fragment found in cervicovaginal fluid from women in labor potentiates the action of ag...
Next Document: The Chinese bamboo leaf odorous frog (Rana (Odorrana) versabilis) and North American Rana frogs shar...